Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado

• Iván Roa ^[3] ; Jeannie Slater ^[4] ; Daniel Carvajal ^[5] ; Kurt Schalper ^[5] ; Gonzalo de Toro ^[6] ; Raúl Ares ^[1] ; Anakaren Game ^[2] ; Jorge León ^[7] ; Xabier de Aretxabala ^[7]
  1. [1] Hospital Padre Hurtado

     Hospital Padre Hurtado

     Santiago, Chile

     
  2. [2] Universidad del Desarrollo

     Universidad del Desarrollo

     Santiago, Chile

     
  3. [3] Creative Bioscience
  4. [4] Clínica Alemana de Santiago Servicio Anatomía Patológica
  5. [5] Universidad de Yale Facultad de Medicina Departamento de Patología
  6. [6] Hospital de Puerto Montt Servicio de Anatomía Patológica
  7. [7] Clínica Alemana de Santiago Departamento de Cirugía

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 141, Nº. 11, 2013, págs. 1411-1419
• Idioma: español
• Títulos paralelos:
  • HER2 gene amplification and overexpression in advanced gastric cancer
• Enlaces
  • Texto completo
• Resumen

  • Background: Overexpression/amplification of the HER2 gene in advanced gastric cancer is a predictor of response to adjuvant therapy with monoclonal antibodies. Aim: To determine the frequency of HER2 gene overexpression and amplification in advanced gastric cancer. Material and Methods: One hundred nine advanced gastric cancer biopsy specimens, from 76 men and 33 women aged 67 ± 14 and 62 ± 12 years respectively, were selected. Three histological patterns (diffuse, intestinal and mixed) were recognized. Automated immunohistochemistry was performed with monoclonal c-erbB-2 (NCL-356) Novocastra. Fluorescent in situ hybridization (FISH) for HER2 was performed in positive cases. Results: In 39% of cases, immunohistochemical staining was negative. It was 1+, 2+ and 3+ positive in 15, 36 and 11% of cases, respectively. It was positive in 16% and 3% of intestinal type and mixed carcinomas, respectively. It was negative in all diffuse carcinomas. FISH was performed in 39 (2 +) cases and in 11 (3 +) cases. The gene amplification was positive in two (2 +) and 11 (3 +) cases (11.9%). The overall concordance between immunohistochemical staining and in situ hybridization was 85%. Conclusions: In advanced gastric cancer, HER2 gene overexpression or amplification was observed in 11% and 12% of cases, respectively.